open access

Vol 64, No 10 (2006)
Other
Published online: 2006-10-31
Submitted: 2012-12-28
Get Citation

Original article
Right ventricular apex versus right ventricular outflow tract pacing: prospective, randomised, long-term clinical and echocardiographic evaluation

Ewa Lewicka-Nowak, Alicja Dąbrowska-Kugacka, Sebastian Tybura, Elżbieta Krzymińska-Stasiuk, Rajmund Wilczek, Justyna Staniewicz, Grażyna Świątecka, Grzegorz Raczak
Kardiol Pol 2006;64(10):1082-1091.

open access

Vol 64, No 10 (2006)
Other
Published online: 2006-10-31
Submitted: 2012-12-28

Abstract

Introduction: In patients treated with permanent pacing, the electrode is typically placed in the right ventricular apex (RVA). Published data indicate that such electrode placement leads to an unfavourable ventricular depolarization pattern, while right ventricular outflow tract (RVOT) pacing seems to be more physiological. Aim: To compare long-term effects of RVOT versus RVA pacing on clinical status, left ventricular (LV) function, and the degree of atrioventricular valve regurgitation. Methods: Patients with indications for permanent pacing, admitted to hospital between 1996 and 1997, were randomised to receive RVA or RVOT pacing. In 2004 during a final control visit in 27 patients clinical status, echocardiographic parameters and QRS complex duration as well as NT-proBNP level were measured. Analysed parameters were compared between groups and in the case of data available during the perioperative period also their evolution in time was assessed. Results: Out of 27 patients 14 were randomised to the RVA group and 13 to the RVOT group. No significant differences between groups were observed before the procedure with respect to age, gender, comorbidities or echocardiographic parameters. Mean duration of pacing did not differ significantly between the groups (89±9 months in RVA group vs 93±6 months in RVOT group, NS). In the RVA group significant LV ejection fraction decrease was observed (from 56±11% to 47±8%, p <0.05); in the RVOT group LV ejection fraction did not change (54±7% and 53±9%; NS). Progression of tricuspid valve regurgitation was also observed in the RVA group but not in the RVOT group. During the final visit NT-proBNP level was significantly higher in the RVA group: 1034±852 pg/ml vs 429±430 pg/ml (p <0.05). Conclusions: In patients with normal LV function permanent RVA pacing leads to LV systolic and diastolic function deterioration. RVOT pacing can reduce the unfavourable effect and can slow down cardiac remodelling caused by permanent RV pacing. Clinical and echocardiographic benefits observed in the RVOT group after 7 years of pacing are reflected by lower NT-proBNP levels in this group of patients.

Abstract

Introduction: In patients treated with permanent pacing, the electrode is typically placed in the right ventricular apex (RVA). Published data indicate that such electrode placement leads to an unfavourable ventricular depolarization pattern, while right ventricular outflow tract (RVOT) pacing seems to be more physiological. Aim: To compare long-term effects of RVOT versus RVA pacing on clinical status, left ventricular (LV) function, and the degree of atrioventricular valve regurgitation. Methods: Patients with indications for permanent pacing, admitted to hospital between 1996 and 1997, were randomised to receive RVA or RVOT pacing. In 2004 during a final control visit in 27 patients clinical status, echocardiographic parameters and QRS complex duration as well as NT-proBNP level were measured. Analysed parameters were compared between groups and in the case of data available during the perioperative period also their evolution in time was assessed. Results: Out of 27 patients 14 were randomised to the RVA group and 13 to the RVOT group. No significant differences between groups were observed before the procedure with respect to age, gender, comorbidities or echocardiographic parameters. Mean duration of pacing did not differ significantly between the groups (89±9 months in RVA group vs 93±6 months in RVOT group, NS). In the RVA group significant LV ejection fraction decrease was observed (from 56±11% to 47±8%, p <0.05); in the RVOT group LV ejection fraction did not change (54±7% and 53±9%; NS). Progression of tricuspid valve regurgitation was also observed in the RVA group but not in the RVOT group. During the final visit NT-proBNP level was significantly higher in the RVA group: 1034±852 pg/ml vs 429±430 pg/ml (p <0.05). Conclusions: In patients with normal LV function permanent RVA pacing leads to LV systolic and diastolic function deterioration. RVOT pacing can reduce the unfavourable effect and can slow down cardiac remodelling caused by permanent RV pacing. Clinical and echocardiographic benefits observed in the RVOT group after 7 years of pacing are reflected by lower NT-proBNP levels in this group of patients.
Get Citation

Keywords

right ventricular apex; right ventricular outflow tract; pacing

About this article
Title

Original article
Right ventricular apex versus right ventricular outflow tract pacing: prospective, randomised, long-term clinical and echocardiographic evaluation

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 64, No 10 (2006)

Pages

1082-1091

Published online

2006-10-31

Bibliographic record

Kardiol Pol 2006;64(10):1082-1091.

Keywords

right ventricular apex
right ventricular outflow tract
pacing

Authors

Ewa Lewicka-Nowak
Alicja Dąbrowska-Kugacka
Sebastian Tybura
Elżbieta Krzymińska-Stasiuk
Rajmund Wilczek
Justyna Staniewicz
Grażyna Świątecka
Grzegorz Raczak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl